Azurity Pharmaceuticals, Inc., a private pharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Zonisade (zonisamide oral suspension), 100 mg/5 mL as adjunctive therapy for the treatment of partial seizures in adults and paediatric patients aged 16 years and older with epilepsy.
